Browse the corpus
Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.
7 passages
Unindicated use of muscle relaxants (e.g., cyclobenzaprine, thiocolchicoside) is low-value. Why: Muscle relaxants should be reserved for specific musculoskeletal conditions; routine use increases sedation and fall risk without proven benefit.
Unindicated NSAID prescriptions for non-inflammatory conditions are low-value. Why: NSAIDs should be reserved for inflammatory pain; their use for non-specific symptoms increases risk of adverse effects without benefit.
Fixed-dose combinations containing serratiopeptidase are low-value and lack evidence for efficacy. Why: Serratiopeptidase has no proven benefit in pain or inflammation; its inclusion in combinations increases cost and pill burden without clinical justification.
Daily doses of NSAIDs (e.g., aceclofenac, etoricoxib) exceeding recommended ceilings are low-value and unsafe. Why: Exceeding maximum daily doses increases risk of gastrointestinal, renal, and cardiovascular adverse effects without additional analgesic benefit.
NSAIDs prescribed without a documented indication are low-value. Why: Multiple findings involve NSAIDs or NSAID combinations prescribed without clear indication.
Prescribing an NSAID (e.g., aceclofenac, etoricoxib) at a total daily dose exceeding the recommended ceiling is proposed as low-value care. Why: Exceeding maximum recommended doses increases the risk of serious adverse events without a corresponding increase in analgesic effect.
Prescribing an alternating regimen of different antipyretics (e.g., paracetamol and ibuprofen) for fever management is low-value care. Why: Alternating antipyretics can increase dosing complexity and risk of error without clear evidence of superior benefit or safety.